FGF21 and hyperlipidemia: Administration of exogenous FGF21, FGF21 analogs, or FGFR1-KLB agonists promotes an array of metabolic benefits in mice that intercept obesity, type 2 diabetes, fatty liver disease, and hyperlipidemia [137,138,139,140,141].